Express News | Next week, 37 stocks will face restrictions lifted, with a cumulative Market Cap of 40.165 billion yuan.

BreakingsMar 22 08:10

Mengkang Pharmaceutical (688373): MRX-4 has completed the Phase III clinical trial in China, and the overseas Innovative Drugs pipeline is progressing steadily.

Event: The company released its 2024 annual report, achieving revenue of 0.13 billion yuan for the year, a significant year-on-year increase of 43.51%; net income attributable to shareholders was -0.441 billion yuan, with losses expanding by 4.65% year-on-year; excluding non-recurring items, net income.

EverbrightMar 20 14:27

Achieved revenue of 0.13 billion yuan in 2024, with multiple milestones in the R&D pipeline being突破.

Shanghai, March 18, 2025 /PR Newswire/ -- On March 17, 2025, Shanghai Mengke Pharmaceutical Co., Ltd. ("Mengke Pharmaceutical" 688373.SH) released its annual report for 2024. In 2024, the company achieved revenue of 0.13 billion yuan, a year-on-year increase of 43.51%. The commercialization process of the core product, Contizolam Tablets, is steadily advancing, and the pipeline under research has also achieved multiple milestone breakthroughs. The commercialization potential of the core product, Contizolam Tablets, continues to be released. As the first self-developed and commercialized new-generation oxazolidinone antibacterial drug of Mengke Pharmaceutical, Contizolam Tablets.

PR NewswireMar 18 10:25

Mengke Pharmaceutical: Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Report

SZSIMar 18 00:00 · Announcements

Mengke Pharmaceutical: Summary of the 2024 Annual Report of Shanghai Mengke Pharmaceutical Co., Ltd.

SZSIMar 18 00:00 · Announcements

Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Annual Report

SZSIMar 18 00:00 · Announcements